What changed in Avantor, Inc.'s latest annual report
In the year ended 31 Dec 2025, Avantor, Inc.'s revenue fell 3.4% to USD 6.55bn, from USD 6.78bn; cash and cash equivalents rose 39.5% to USD 365.40m, from USD 261.90m; long-term debt rose 21% to USD 3.92bn, from USD 3.23bn.
Year ended 31 Dec 2025. Source: 10-K filed 11 Feb 2026, read it on SEC EDGAR.
USD 6.78bn to USD 6.55bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 6.78bn | 6.55bn | Down 3.4% |
| Net income | 711.50m | -530.20m | Not comparable |
| Total assets | 12.11bn | 11.79bn | Down 2.6% |
| Total liabilities | 6.16bn | 6.23bn | Up 1.2% |
| Long-term debt | 3.23bn | 3.92bn | Up 21% |
| Cash and cash equivalents | 261.90m | 365.40m | Up 39.5% |
| Shareholders' equity | 5.96bn | 5.57bn | Down 6.6% |
Questions people ask
Did Avantor, Inc.'s revenue grow last year?
Revenue fell 3.4%, from USD 6.78bn to USD 6.55bn in the year ended 31 Dec 2025.
Is Avantor, Inc. profitable?
Not in its latest year: it reported a net loss of USD 530.20m in the year ended 31 Dec 2025. The year before: USD 711.50m.
How much cash and debt does Avantor, Inc. have?
At its latest year end (31 Dec 2025), Avantor, Inc. reported cash and cash equivalents of USD 365.40m and long-term debt of USD 3.92bn.
Where do these numbers come from?
From Avantor, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Avantor, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Laboratory Analytical Instruments companies
- Agilent Technologies, Inc.Cash and cash equivalents up 34.6%
- Waters CorporationCash and cash equivalents up 80.7%
- Illumina, Inc.Shareholders' equity up 14.7%
- Mettler-Toledo International Inc.Total assets up 14.6%
- Revvity, IncCash and cash equivalents down 20.9%
- 10x Genomics, Inc.Total liabilities up 17.5%
- Bio-Rad Laboratories, Inc.Shareholders' equity up 13.5%